ArticleJournal of medical virology2026
Temporal Dynamics of Viremia in Hemorrhagic Fever With Renal Syndrome Patients.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Temporal Dynamics of Viremia in Hemorrhagic Fever With Renal Syndrome Patients.Journal of medical virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of hemorrhagic fever with renal syndrome (HFRS) remains incompletely understood. Currently, the clinical diagnosis of HFRS primarily relies on epidemiological history and clinical presentation, while the confirmation of HFRS depends mainly on the detection of hemorrhagic fever antibodies. As a viral disease, etiological diagnosis has yet to be widely implemented in clinical practice. We conducted a prospective study to characterize the temporal pattern of viremia in patients with HFRS and to explore the relationship between viral load and key laboratory parameters. Demographic and clinical data were collected from HFRS patients admitted to Tangdu Hospital, The Fourth Military Medical University, between December 2021 and December 2022. Serum samples obtained at different illness stages were tested for viral load using RT-PCR, and corresponding laboratory results were analyzed. A total of 61 patients were enrolled, providing 256 serum samples. Both viral detection rate and viral load decreased with disease progression, with viremia detectable up to day 22. Regardless of clinical severity, Hantaan virus (HTNV) RNA load declined over time. Viral load was positively correlated with white blood cell count, lymphocyte count, and monocyte count (r = 0.428, 0.485, and 0.318, respectively; all p < 0.001), negatively correlated with platelet count (r = -0.507, p < 0.001), and showed weak correlations with hemoglobin and neutrophil count. Additionally, viral load was negatively correlated with fibrinogen (r = -0.502, p < 0.001) and weakly correlated with prothrombin time, activated partial thromboplastin time, and prothrombin activity; it was positively correlated with the aspartate aminotransferase-to-platelet ratio index (r = 0.515, p < 0.001). In conclusion, viremia occurs early in HFRS onset, can persist for more than 2 weeks, and viral load is an important indicator for early diagnosis of HFRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.